FDA Grants Breakthrough Therapy Designation to Durvalumab for NSCLC
The FDA granted breakthrough therapy designation to durvalumab for patients with locally advanced, unresectable NSCLC who do not relapse after platinum-based chemoradiation.
AACR 2013
High Tumor HER2 Predicts Greatest Benefit from T-DM1 Breast Cancer Treatment
Women with metastatic, HER2-positive breast cancer with tumors that express high levels of HER2 derived the greatest survival benefit from treatment with trastuzumab emtansine (T-DM1), according to research presented at AACR 2013.
Autologous-Collected T-Cell Immunotherapy Shows Promising Antileukemia Activity in Children
Using autologous T-cell immunotherapy to attack leukemia cells showed early promise in two children diagnosed with relapsing acute lymphoblastic leukemia after bone marrow transplant, according to research presented at AACR 2013.
Survivors of Melanoma Need to Remain Vigilant About Sun Exposure, Tanning Beds
Melanoma survivors often do not take protective measures to prevent skin cancer recurrence, according to research presented at AACR 2013.
Prevalence of Benign Findings after Lung Surgery Varies Geographically
The number of benign findings for suspected lung cancers varies by state, suggesting a national lung cancer screening program would vary geographically, according to research presented at AACR 2013.
PLK1-Targeting RNAi Drug is Well-Tolerated and Demonstrates Potential Therapeutic Benefit
The RNA interference (RNAi) drug TKM-080301 can be safely administered to patients with advanced solid tumors or lymphoma, and some patients show therapeutic benefit, according to research presented at AACR 2013.
Higher Incidence of Childhood ALL, Retinoblastoma, Germ Cells Tumors Linked to Air Pollution
Increased exposure to traffic-related air pollution during pregnancy and early life was associated with a higher incidence of acute lymphoblastic leukemia, retinoblastoma, and germ cell tumors, according to research presented at AACR 2013.
In KRAS-Mutant Non-Small Cell Lung Cancer, Biomarkers May Predict Sensitivity to Combined MEK/PI3K Inhibition
Newly identified biomarkers may predict sensitivity to combined MEK and PI3K inhibition in patients with KRAS-mutant NSCLC, according to research presented at AACR 2013.
Novel AKT Pathway Inhibitor ARQ 092 Safe in Phase 1 Trial
The novel oral selective AKT pathway inhibitor ARQ 092 exhibits a manageable safety profile among patients with advanced solid tumors, according to research presented at AACR 2013.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...